Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review

Michaela Fesenfeld, Raymond Hutubessy, Mark Jit

Research output: Contribution to journalReview articlepeer-review

Abstract

The World Health Organization recommends establishing that human papillomavirus vaccination is cost-effective before vaccine introduction. We searched Pubmed, Embase and the Cochrane Library to 1 April 2012 for economic evaluations of human papillomavirus vaccination in low and middle income countries. We found 25 articles, but almost all low income countries and many middle income countries lacked country-specific studies. Methods, assumptions and consequently results varied widely, even for studies conducted for the same country. Despite the heterogeneity, most studies conclude that vaccination is likely to be cost-effective and possibly even cost saving, particularly in settings without organized cervical screening programmes. However, study uncertainty could be reduced by clarity about vaccine prices and vaccine delivery costs. The review supports extending vaccination to low income settings where vaccine prices are competitive, donor funding is available, cervical cancer burden is high and screening options are limited.

Original languageEnglish (US)
Pages (from-to)3786-3804
Number of pages19
JournalVaccine
Volume31
Issue number37
DOIs
StatePublished - Aug 20 2013

Keywords

  • Cervical screening
  • Cost-effectiveness
  • Developing countries
  • Human papillomavirus
  • Vaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review'. Together they form a unique fingerprint.

Cite this